71.21 +0.22 (0.31%)
After hours: 7:14PM EDT
|Bid||71.15 x 1400|
|Ask||72.50 x 900|
|Day's Range||70.73 - 74.48|
|52 Week Range||1.91 - 75.95|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||19.49|
|Earnings Date||Jul. 21, 2020 - Jul. 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||91.98|
Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (NYSE: EW) shares rose 15.3% in April, according to data provided by S&P Global Market Intelligence. Edwards Lifesciences, like many other companies across industries, fell in March as the coronavirus outbreak deepened in the U.S. With stay-at-home orders issued across the country, investors worried about the impact of the health crisis on businesses' earnings. Transcatheter aortic valve replacement (TAVR) with the Sapien 3 continued to show favorable results for these patients compared with surgery.
Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients. This approval was granted following an interim order issued by Health Canada to address the pressing need for medical supplies used in the response to the COVID-19 pandemic. Hemodynamic monitoring refers to the measurement and tracking of different vital signs that help manage blood flow and oxygenation in critically ill patients, like those who are being treated for COVID-19.
NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Edwards Lifesciences Corp. (NYSE:EW) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 5:00 ...
The Senate approved a new $484 billion stimulus bill on Tuesday, marking another phase of government support and leaving many wondering how the money will be dispersed. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus.
Edwards Lifesciences Corporation (NYSE:EW) received a lot of attention from a substantial price movement on the NYSE...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Edwards Lifesciences...
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Last week, you might have seen that Edwards Lifesciences Corporation (NYSE:EW) released its annual result to the...
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.35% and 1.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...